FindTrial
Sign In

Role of Gene Sequencing Analysis in Colon and Rectal Cancer

Prognostic And Therapeutic Implication Of Next Generation Sequencing In Metastatic Colorectal Cancer (mCRC) - NIL

Status
Active, not recruiting
Phases
Unknown
Study type
Observational
Source
CTRI
Registry ID
CTRI/2023/10/059098
Enrollment
65
Registered
2023-10-25
Start date
Unknown
Completion date
Unknown
Last updated
2023-11-13

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Health Condition 1: C189- Malignant neoplasm of colon, unspecified Health Condition 2: C19- Malignant neoplasm of rectosigmoidjunction Health Condition 3: C20- Malignant neoplasm of rectum

Interventions

Intervention1: Nil: Nil

Sponsors

Institute of Medical sciences and SUM Hospital SOA University
Lead Sponsor

Eligibility

Inclusion criteria

Inclusion criteria: All confirmed cases of mCRC attending the medical oncology, Surgical Oncology, Gastrosurgery and Gastroenterology OPD.

Exclusion criteria

Exclusion criteria: 1. Age 2. Consent refusal for NGS and RT-PCR. 3. Patient who had insufficient tissue sample in block for NGS/RT-PCR analysis

Design outcomes

Primary

MeasureTime frame
To evaluate the frequency of KRAS, NRAS, BRAF,HER2,PIK3CA,TP53 & NTRK mutations in cases of mCRC by NGS.Timepoint: Baseline—

Secondary

MeasureTime frame
To compare the sensitivity, specificity and concordance rates of KRAS,NRAS and BRAF mutation analysis detected by NGS with PCR in colorectal tissue samples.Timepoint: Baseline;To evaluate the Response Rate and Progression free survival (PFS 1) with respect to mutations in cases of metastatic colorectal cancer.Timepoint: 3 months, 6 months, 9 months, 12 months—

Countries

India

Contacts

Public ContactDr Soumya Surath Panda

Institute of Medical sciences and SUM Hospital

soumyasurathpanda@soa.ac.in8895370579

Outcome results

None listed

Source: CTRI (via WHO ICTRP) · Data processed: Feb 4, 2026